{"id":54440,"date":"2023-03-02T17:03:11","date_gmt":"2023-03-02T16:03:11","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex\/"},"modified":"2023-03-02T17:03:11","modified_gmt":"2023-03-02T16:03:11","slug":"harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex\/","title":{"rendered":"Harris Williams Acts as Exclusive Financial Advisor to Thoma Bravo on its Investment in LOGEX"},"content":{"rendered":"
\n

LONDON–(BUSINESS WIRE)–Harris Williams<\/a>, a global investment bank specializing in M&A advisory services, announces it acted as exclusive financial advisor to Thoma Bravo, a leading software investment firm, on its investment in LOGEX, a portfolio company of Summa Equity. LOGEX is a leading healthcare analytics provider, which uses data to help healthcare providers and hospitals make better decisions and deliver optimum health outcomes for patients while reducing costs. LOGEX\u2019s existing shareholders, the company\u2019s founders, and Summa Equity will remain invested with the business and will work closely with Thoma Bravo and the executive committee to support LOGEX\u2019s European growth and further drive innovation in healthcare analytics. The transaction was led by Julien Oussadon<\/a>, Sylvain Noblet<\/a> and Luke Clifford of the Harris Williams Technology Group<\/a>.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe are delighted to have advised Thoma Bravo on its inaugural investment by its Europe-based team,\u201d said Julien Oussadon, a managing director at Harris Williams. \u201cThis transaction underscores our long-standing relationship with Thoma Bravo, and we look forward to watching the firm\u2019s continued success as it embarks on its European expansion.\u201d\n<\/p>\n

\n\u201cLOGEX has established itself as a category leader in healthcare analytics, enabling stakeholders to make better, data-driven decisions to maximize impact,\u201d said Sylvain Noblet, a director at Harris Williams. \u201cLOGEX has found a fantastic new partner to further accelerate its offering.\u201d\n<\/p>\n

\nThoma Bravo is one of the largest software investors in the world, with more than $120 billion in assets under management as of September 30, 2022. Through its private equity, growth equity, and credit strategies, the firm invests in growth-oriented, innovative companies operating in the software and technology sectors. Leveraging Thoma Bravo\u2019s deep sector expertise and strategic and operational capabilities, the firm collaborates with its portfolio companies to implement operating best practices and drive growth initiatives. Over the past 20 years, the firm has acquired or invested in more than 420 companies representing over $235 billion in enterprise value (including control and non-control investments). The firm has offices in Chicago, London, Miami and San Francisco.\n<\/p>\n

\nLOGEX is leading the way in healthcare analytics in Europe. By turning data into actionable insights, LOGEX helps solve the complex healthcare challenge of managing costs whilst improving clinical outcomes. Headquartered in Amsterdam and with an international team of over 450 members, LOGEX helps over 700 public and private healthcare providers make data-driven decisions that level up patient outcomes everywhere and make the best possible care more affordable for everyone.\n<\/p>\n

\nHarris Williams<\/a> is a global investment bank specializing in M&A advisory services. Clients worldwide rely on us to help unlock value in their business and turn ambitious goals into reality. We approach every engagement with boundless collaboration, pooling expertise and relationships across industries and geographies to uncover the unique story of each company. For over 30 years, our clients have trusted us to think strategically, execute precisely, and deliver premium outcomes through M&A.\n<\/p>\n

\nTechnology is ubiquitous in today\u2019s global economy, with most sectors and industries rapidly adopting software and data solutions as companies seek to increase competitiveness and enhance productivity. Led by seasoned and passionate professionals with strong vertical and horizontal experience, the Harris Williams Technology Group<\/a> partners with both growth capital and private equity investors as well as company leaders around the globe. Our clients rely on us to navigate the ever-evolving technology M&A landscape. Our Technology Group has deep expertise across application and vertical software as well as technology and data services.\n<\/p>\n

\nHarris Williams LLC is a registered broker-dealer and member of FINRA and SIPC. Harris Williams & Co. Ltd is a private limited company incorporated under English law with its registered office at 8th Floor, 20 Farringdon Street, London EC4A 4AB, UK, registered with the Registrar of Companies for England and Wales (registration number 07078852). Harris Williams & Co. Ltd is authorized and regulated by the Financial Conduct Authority. Harris Williams & Co. Corporate Finance Advisors GmbH is registered in the commercial register of the local court of Frankfurt am Main, Germany, under HRB 107540. The registered address is Bockenheimer Landstrasse 33-35, 60325 Frankfurt am Main, Germany (email address: hwgermany@harriswilliams.com<\/a>). Gesch\u00e4ftsf\u00fchrer\/Directors: Jeffery H. Perkins, Paul Poggi. (VAT No. DE321666994). Harris Williams is a trade name under which Harris Williams LLC, Harris Williams & Co. Ltd and Harris Williams & Co. Corporate Finance Advisors GmbH conduct business.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nFor media inquiries, please contact at media@harriswilliams.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LONDON–(BUSINESS WIRE)–Harris Williams, a global investment bank specializing in M&A advisory services, announces it acted as exclusive financial advisor to Thoma Bravo, a leading software investment firm, on its investment in LOGEX, a portfolio company of Summa Equity. LOGEX is a leading healthcare analytics provider, which uses data to help healthcare providers and hospitals make … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54440","6":"format-standard","7":"category-industry"},"yoast_head":"\nHarris Williams Acts as Exclusive Financial Advisor to Thoma Bravo on its Investment in LOGEX - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Harris Williams Acts as Exclusive Financial Advisor to Thoma Bravo on its Investment in LOGEX - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LONDON–(BUSINESS WIRE)–Harris Williams, a global investment bank specializing in M&A advisory services, announces it acted as exclusive financial advisor to Thoma Bravo, a leading software investment firm, on its investment in LOGEX, a portfolio company of Summa Equity. LOGEX is a leading healthcare analytics provider, which uses data to help healthcare providers and hospitals make ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-02T16:03:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230302005649\/en\/683130\/21\/HW_Logo_HorizontalColor.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Harris Williams Acts as Exclusive Financial Advisor to Thoma Bravo on its Investment in LOGEX\",\"datePublished\":\"2023-03-02T16:03:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex\\\/\"},\"wordCount\":743,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230302005649\\\/en\\\/683130\\\/21\\\/HW_Logo_HorizontalColor.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex\\\/\",\"name\":\"Harris Williams Acts as Exclusive Financial Advisor to Thoma Bravo on its Investment in LOGEX - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230302005649\\\/en\\\/683130\\\/21\\\/HW_Logo_HorizontalColor.jpg\",\"datePublished\":\"2023-03-02T16:03:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230302005649\\\/en\\\/683130\\\/21\\\/HW_Logo_HorizontalColor.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230302005649\\\/en\\\/683130\\\/21\\\/HW_Logo_HorizontalColor.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Harris Williams Acts as Exclusive Financial Advisor to Thoma Bravo on its Investment in LOGEX\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Harris Williams Acts as Exclusive Financial Advisor to Thoma Bravo on its Investment in LOGEX - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex\/","og_locale":"en_US","og_type":"article","og_title":"Harris Williams Acts as Exclusive Financial Advisor to Thoma Bravo on its Investment in LOGEX - Pharma Trend","og_description":"LONDON–(BUSINESS WIRE)–Harris Williams, a global investment bank specializing in M&A advisory services, announces it acted as exclusive financial advisor to Thoma Bravo, a leading software investment firm, on its investment in LOGEX, a portfolio company of Summa Equity. LOGEX is a leading healthcare analytics provider, which uses data to help healthcare providers and hospitals make ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-02T16:03:11+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230302005649\/en\/683130\/21\/HW_Logo_HorizontalColor.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Harris Williams Acts as Exclusive Financial Advisor to Thoma Bravo on its Investment in LOGEX","datePublished":"2023-03-02T16:03:11+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex\/"},"wordCount":743,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230302005649\/en\/683130\/21\/HW_Logo_HorizontalColor.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex\/","url":"https:\/\/pharma-trend.com\/en\/harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex\/","name":"Harris Williams Acts as Exclusive Financial Advisor to Thoma Bravo on its Investment in LOGEX - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230302005649\/en\/683130\/21\/HW_Logo_HorizontalColor.jpg","datePublished":"2023-03-02T16:03:11+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230302005649\/en\/683130\/21\/HW_Logo_HorizontalColor.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230302005649\/en\/683130\/21\/HW_Logo_HorizontalColor.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/harris-williams-acts-as-exclusive-financial-advisor-to-thoma-bravo-on-its-investment-in-logex\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Harris Williams Acts as Exclusive Financial Advisor to Thoma Bravo on its Investment in LOGEX"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54440","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54440"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54440\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54440"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54440"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54440"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}